ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 INTEGRATE IIa Randomised, Double-Blind, Phase III Study: Regorafenib vs. Placebo in Refractory Advanced Gastro-Esophageal Cancer

148 views
February 23, 2023
Comments 0
Login to view comments. Click here to Login